Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
advice, beneficiary, Biden, bulk, cancer, CFO, column, concept, Congressional, counter, Deloitte, donut, encourage, erosion, Finnacial, gastrointestinal, hole, hyperinflammtory, IL, Inflamed, inhibiting, instructed, IRA, Jonathan, liver, marketplace, MedTech, mistakenly, Num, Obama, Offcier, ommencing, prelinical, proof, reexamining, sequester, singed, skin, Solomon, stipulated, Storm, sutdy, swelling, synovium, Taxpayer, thickening, unnecessary, VAT, weighed, XX
Removed:
allocation, reduction, supporting
Filing tables
Filing exhibits
RAPH similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the annual report of Raphael Pharmaceutical Inc., or the Company, on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Shlomo Pilo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: March 24, 2023 | /s/ Shlomo Pilo |
| Shlomo Pilo | |
| Chief Executive Officer | |
| (Principal Executive Officer) |